Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HCR-188
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Helicore Doses First Participant in Phase 1 Trial of HCR-188 for Obesity
Details : HCR-188 is a first-in-class GIP antagonist, antibody candidate, which is currently being evaluated for the treatment of obesity.
Product Name : HCR-188
Product Type : Antibody
Upfront Cash : Inapplicable
March 25, 2025
Lead Product(s) : HCR-188
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
